PixarBio (PixarBio) Cash Flow from Others : $0.01 Mil (TTM As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Cash Flow from Others?

PixarBio's cash flow from others for the three months ended in Sep. 2016 was $0.01 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Sep. 2016 was $0.01 Mil.

PixarBio Cash Flow from Others Historical Data

The historical data trend for PixarBio's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Cash Flow from Others Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Cash Flow from Others

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Cash Flow from Others	Get a 7-Day Free Trial					-	-	-	-	0.01

PixarBio Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.

PixarBio Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of PixarBio's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio (PixarBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.